FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2782739835> ?p ?o ?g. }

• W2782739835 endingPage "19" @default.
• W2782739835 startingPage "17" @default.
• W2782739835 abstract "Infusions of aminobisphosphonates are now established therapies ofpostmenopausal osteoporosis. Their use is associated with fever and musculoskeletal pain in some subjects, referred to as the acute phase response (APR). The purpose of the study was to explore tolerability of zoledronic acid in the treatment of postmenopausal osteoporosis. In a 36-month open label, prospective study patients with postmenopausal osteoporosis iv received zoledronic acid at a dose of 5 mg every 12 months. We then analyzed the tolerability of the treatment at the hospital and via telephone interviews during the next 14 days and every 3 months after the infusion. Prevention of APR was carried out with paracetamol 500 mg x 3 times a day on the day of first infusion and the next 2 days. Symptoms of APR were recorded in 39% (n=43) of patients with prevention therapy. APR developed in the first 12-24 hours after infusion of zoledronic acid. Among women without prevention APR developed in 65% (n=75) of cases. (OR=0.34 CI (0.2-0.59)). After the 2 nd infusion symptoms of APR were noted in 27.9% (n=26) (р<0.05) of 93 patients, after the 3 rdin 6.6% (n=2) of 30 patients. Thus, in >90% of cases the symptoms were of mild or moderate severity, with resolution within 3 days after infusion of zoledronic acid. The most frequent symptoms were bone and muscular manifestations and a flu-like syndrome (p<0.05). APR developed during the first 12-24 hours after infusion of zoledronic acid. ARR developed 2.5 times more often in the cases when zoledronic acid was used for the first time. If paracetamol treatment was administered, APR cases were documented 1.7 times less often with lesser degree and length of manifestations. Frequency of APR dropped after repeated zoledronic acid infusions." @default.
• W2782739835 created "2018-01-26" @default.
• W2782739835 creator A5057435989 @default.
• W2782739835 creator A5069004390 @default.
• W2782739835 creator A5069169844 @default.
• W2782739835 date "2013-12-15" @default.
• W2782739835 modified "2023-09-25" @default.
• W2782739835 title "TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH NITROGEN CONTAINING BISPHOSPHONATES, EARLY SIDE EFFECTS AND THEIR PREVENTION" @default.
• W2782739835 doi "https://doi.org/10.14341/osteo2013317-19" @default.
• W2782739835 hasPublicationYear "2013" @default.
• W2782739835 type Work @default.
• W2782739835 sameAs 2782739835 @default.
• W2782739835 citedByCount "0" @default.
• W2782739835 crossrefType "journal-article" @default.
• W2782739835 hasAuthorship W2782739835A5057435989 @default.
• W2782739835 hasAuthorship W2782739835A5069004390 @default.
• W2782739835 hasAuthorship W2782739835A5069169844 @default.
• W2782739835 hasBestOaLocation W27827398351 @default.
• W2782739835 hasConcept C126322002 @default.
• W2782739835 hasConcept C141071460 @default.
• W2782739835 hasConcept C197934379 @default.
• W2782739835 hasConcept C2776326535 @default.
• W2782739835 hasConcept C2776541429 @default.
• W2782739835 hasConcept C2778375690 @default.
• W2782739835 hasConcept C71924100 @default.
• W2782739835 hasConceptScore W2782739835C126322002 @default.
• W2782739835 hasConceptScore W2782739835C141071460 @default.
• W2782739835 hasConceptScore W2782739835C197934379 @default.
• W2782739835 hasConceptScore W2782739835C2776326535 @default.
• W2782739835 hasConceptScore W2782739835C2776541429 @default.
• W2782739835 hasConceptScore W2782739835C2778375690 @default.
• W2782739835 hasConceptScore W2782739835C71924100 @default.
• W2782739835 hasIssue "3" @default.
• W2782739835 hasLocation W27827398351 @default.
• W2782739835 hasOpenAccess W2782739835 @default.
• W2782739835 hasPrimaryLocation W27827398351 @default.
• W2782739835 hasRelatedWork W116851606 @default.
• W2782739835 hasRelatedWork W2002120878 @default.
• W2782739835 hasRelatedWork W2003938723 @default.
• W2782739835 hasRelatedWork W2026111001 @default.
• W2782739835 hasRelatedWork W2047967234 @default.
• W2782739835 hasRelatedWork W2101347557 @default.
• W2782739835 hasRelatedWork W2390541474 @default.
• W2782739835 hasRelatedWork W2439875401 @default.
• W2782739835 hasRelatedWork W2782739835 @default.
• W2782739835 hasRelatedWork W4309691976 @default.
• W2782739835 hasVolume "16" @default.
• W2782739835 isParatext "false" @default.
• W2782739835 isRetracted "false" @default.
• W2782739835 magId "2782739835" @default.
• W2782739835 workType "article" @default.